Home › NDC Lookup › Ingredients › Polyethylene Glycol-3350 And Electrolyte... › 43386-0060-19
GaviLyte - C TM polyethylene glycol-3350 and electrolytes with Flavor Pack 3350 240 g/278.26g; 5.84 g/278.26g; 2.98 g/278.26g; 6.72 g/278.26g; 22.72 g/278.26g Powder, For Solution, 278.26 g — NDC 43386-0060-19 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

GaviLyte - C TM polyethylene glycol-3350 and electrolytes with Flavor Pack 3350 240 g/278.26g; 5.84 g/278.26g; 2.98 g/278.26g; 6.72 g/278.26g; 22.72 g/278.26g Powder, For Solution, 278.26 g — NDC 43386-060-19 (Billing 43386-0060-19)

by Lupin Pharmaceuticals,Inc. · 278.26 g in 1 BOTTLE

This is a package of 278.26 g of GaviLyte - C TM polyethylene glycol-3350 and electrolytes with Flavor Pack 3350 240 g/278.26g; 5.84 g/278.26g; 2.98 g/278.26g; 6.72 g/278.26g; 22.72 g/278.26g Powder, For Solution from Lupin Pharmaceuticals,Inc., marketed since Jan 2009 and currently FDA-listed; retail pharmacies pay about $0.0039 per mL (NADAC). It is this product's only package size.

NDC 43386-0060-19
🏷️ FDA NDC (as labeled) 43386-060-19 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Past resolved recalls for this product (2)
Class II · Apr 27, 2022 · Terminated — Failed Stability Specification (Lupin Pharmaceuticals Inc.) · FDA recall D-0875-2022
Class II · Jul 29, 2021 · Terminated — Failed Stability Specification; Out of specification for Osmolarity (Novel Laboratories, Inc. d.b.a LUPIN) · FDA recall D-0726-2021

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 43386-060-19
Product NDC 43386-060
11-digit billing NDC 43386006019
NCPDP billing unit ML — per mL (volume)
RxCUI 966914, 967023
UNII G2M7P15E5P, 451W47IQ8X, 660YQ98I10, 8MDF5V39QO, 36KCS0R750
Application # ANDA090186
SPL Set ID a8b15625-ca7c-4d57-9f36-3ac2a6d13665
Established class (EPC) Osmotic Laxative
Mechanism of action Osmotic Activity
Physiologic effect Stimulation Large Intestine Fluid/Electrolyte Secretion
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2009-01-06
Route ORAL
Dosage form POWDER, FOR SOLUTION
Substance POLYETHYLENE GLYCOL 3350; SODIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM SULFATE ANHYDROUS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 46992005302140
GPI class GaviLyte-C
GCN Seq No 062659
GCN 98433
HICL code 034667
Ingredient (HICL) Peg3350/Sod Sulf,Bicarb,Cl/Kcl
HIC1 code D
Therapeutic class — broad (HIC1) Biliary System/Gastro-Intestinal System
HIC2 code D6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Colon
HIC3 code D6S
Therapeutic class — specific (HIC3) Laxatives And Cathartics
AHFS code 56:12.00.00
AHFS class Cathartics And Laxatives
FDB label name GAVILYTE-C SOLUTION
FDB brand name Gavilyte-C
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 062659
  • GCN: 98433
  • GPI-14 (Medi-Span): 46992005302140
  • HICL (First Databank): 034667
  • AHFS class code: 56:12.00.00
  • RxCUI (RxNorm): 966914
Why two NDCs? The FDA registers this code as 43386-060-19 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 43386-0060-19. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Osmotic Laxative class.

Pharmacologic class Osmotic Laxative
How it works Osmotic Activity
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name GAVILYTE-C SOLUTION Ingredient Peg3350/Sod Sulf,Bicarb,Cl/Kcl
📖 What it is MedlinePlus · NLM

Polyethylene glycol-electrolyte solution (PEG-ES) is used to empty the colon (large intestine, bowel) before a colonoscopy (examination of the inside of the colon to check for colon cancer and other abnormalities) or barium enema (a test in which the colon is filled with a fluid and then x-rays are taken) so that the doctor will have a clear view of the walls of the colon. PEG-ES is in a class of medications called osmotic laxatives. It works by causing watery diarrhea so that the stool can be emptied from the colon. The medication also contains electrolytes to prevent dehydration and other se...

Read the full MedlinePlus article ↗

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.004 —
Medicaid paysCMS SDUD · 12 mo $0.0056 —
Medicare drug plans payPart D · Q2 2026 $0.0056 —
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Aug 2022 Jan 2026 Sep 2026 $0.004 $0.002
▲ Up 44% over the last 23 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
43386-0060-19 You're viewing this Main listing 278.26 g in 1 BOTTLE Sample 2009-06-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
GaviLyte - C TM 3350 240 g/278.26g; 5.84 g/278.26g; 2.98 g/278.26g; 6.72 g/278.26g; 22.72 g/278.26gthis 43386-0060-19 Lupin 278.26 g $0.004 — Availability likely —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2009
On the market since
Jan 2009
📍
2026
Currently FDA-listed
17 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

FlavorLemon
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 7CVR7L4A2D
    A starch-derived carbohydrate produced by breaking down corn, potato, or tapioca starch. It functions as a filler and binder to give the medicine bulk and texture, and sometimes as a mild sweetener or texture enhancer in powders and tablets.
  • UNII SB8ZUX40TY
    Saccharin sodium is an artificial sweetener made from saccharin salt. It's added to medicines to improve taste, especially in liquid formulations for children or bitter drugs.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerLupin Pharmaceuticals,Inc.
Application holderNOVEL LABORATORIES INC
FDA applicationANDA090186 (ANDA)
Labeler code43386
First marketedJan 2009
Product typeHuman Prescription Drug
Portfolio89 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 21 words ▾

INDICATIONS AND USAGE GaviLyte- C with flavor pack is indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.

⏱️ Dosage and Administration ~1 min read ▾

DOSAGE AND ADMINISTRATION GaviLyte- C with flavor pack can be administered orally or by nasogastric tube. Patients should fast at least 3 hours prior to administration. A one hour waiting period after the appearance of clear liquid stool should be allowed prior to examination to complete bowel evacuation.

No foods except clear liquids should be permitted prior to examination after GaviLyte- C with flavor pack administration. ORAL: The recommended adult oral dose is 240 mL (8 fl. oz.) every 10 minutes (see INFORMATION FOR PATIENTS). Lavage is complete when fecal discharge is clear.

Lavage is usually complete after the ingestion of 3 to 4 liters. NASOGASTRIC TUBE: GaviLyte- C with flavor pack is administered at a rate of 20 to 30 mL per minute (1.2 to

1.8L/hour). PREPARATION OF GaviLyte- C with flavor pack SOLUTION: This preparation can be used with or without the lemon flavor pack. 1.

To add flavor, tear open lemon flavor pack at the indicated marking and pour contents into the bottle BEFORE reconstitution. 2. SHAKE WELL to incorporate flavoring into the powder.

3. Add tap water to FILL line. Replace cap tightly and mix or shake well until all ingredients have dissolved.

(No other additional ingredients, e.g. flavorings, should be added to the solution.) Note: If not using flavor pack, omit steps one and two, above.

⛔ Contraindications 41 words ▾

CONTRAINDICATIONS GaviLyte- C with flavor pack is contraindicated in patients known to be hypersensitive to any of the components. GaviLyte- C with flavor pack is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon.

⚠️ Warnings 46 words ▾

WARNINGS Flavor pack is for use only in combination with the contents of the accompanying 4 liter container. No other additional ingredients (e.g., flavorings) should be added to the solution. GaviLyte- C with flavor pack should be used with caution in patients with severe ulcerative colitis.

🤒 Adverse Reactions 57 words ▾

ADVERSE REACTIONS Nausea, abdominal fullness and bloating are the most frequent adverse reactions, occurring in up to 50% of patients. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient. Isolated cases of urticaria, rhinorrhea, dermatitis, and rarely anaphylaxis, angioedema, tongue edema, and face edema have been reported which may represent allergic reactions.

🧬 Clinical Pharmacology 53 words ▾

CLINICAL PHARMACOLOGY GaviLyte- C with flavor pack cleanses the bowel by induction of diarrhea. The osmotic activity of polyethylene glycol 3350, in combination with the electrolyte concentration, results in virtually no net absorption or excretion of ions or water. Accordingly, large volumes may be administered without significant changes in fluid and electrolyte balance.

📦 How Supplied / Storage and Handling 127 words ▾

HOW SUPPLIED GaviLyte- C with flavor pack is supplied in 4 liter bottles with an attached lemon flavor pack. Each 4 liter bottle contains polyethylene glycol-3350 240 g, sodium chloride 5.84 g, potassium chloride 2.98 g, sodium bicarbonate 6.72 g, sodium sulfate (anhydrous) 22.72 g. This preparation is supplied in powdered form, for oral administration as a solution.

GaviLyte- C with flavor pack 4liter: NDC 43386-060-19 Store at 20° to 25°C (68° to 77°F): excursions permitted between 15° to 30°C (59° to 86°F). KEEP RECONSTITUTED SOLUTION REFRIGERATED. USE WITHIN 48 HOURS.

DISCARD UNUSED PORTION. LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc. Manufactured by: Novel Laboratories, Inc.

Somerset, NJ 08873, USA Manufactured for: Lupin Pharmaceuticals, Inc. Naples FL, 34108 SAP Code: 278922 Rev. 11/2024 Image

📋 Description 133 words ▾

DESCRIPTION GaviLyte- C with flavor pack is a white, colon lavage preparation provided as water-soluble components for solution. In solution this preparation with lemon flavor pack added delivers the following, in grams per liter. Polyethylene glycol 3350 240.00 Sodium chloride

5.84 Potassium chloride

6.72 Sodium bicarbonate

2.98 Sodium sulfate

22.72Flavor ingredients 0.500 When dissolved in sufficient water to make 4 liters, the final solution contains 125 mEq/L sodium, 10 mEq/L potassium, 20 mEq/L bicarbonate, 80 mEq/L sulfate, 35 mEq/L chloride and 18 mEq/L polyethylene glycol 3350. The reconstituted solution is an isosmotic solution, for oral administration, having mild salty taste. This preparation can be used without the lemon flavor pack and is administered orally or via nasogastric tube.

Each lemon flavor pack (2 g) contains natural lemon flavor powder, saccharin sodium, maltodextrin.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Patients with impaired gag reflex, unconscious or semiconscious patients and patients prone to regurgitation or aspiration should be observed during the administration of GaviLyte- C with flavor pack, especially if it is administered via nasogastric tube. If gastrointestinal obstruction or perforation is suspected appropriate studies should be performed to rule out these conditions before administration of GaviLyte- C with flavor pack. INFORMATION FOR PATIENTS GaviLyte- C with flavor pack produces a watery stool which cleanses the bowel prior to examination.

For best results, no solid food should be ingested during the 3 to 4 hour period prior to the initiation of GaviLyte- C with flavor pack administration. In no case should solid foods be eaten within 2 hours of drinking GaviLyte- C with flavor pack. The rate of administration is 240 mL (8 fl. oz.) every 10 minutes.

Rapid drinking of each portion is preferred rather than drinking small amounts continuously. The first bowel movement should occur approximately one hour after the start of GaviLyte- C with flavor pack administration. Administration of GaviLyte- C with flavor pack should be continued until the watery stool is clear and free of solid matter.

This normally requires the consumption of approximately 3 to 4 liters (3 to 4 quarts), although more or less may be required in some patients. The unused portion should be discarded. DRUG INTERACTIONS Oral medication administered within one hour of start of administration of GaviLyte- C with flavor pack may be flushed from the gastrointestinal tract and not absorbed.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY Studies to evaluate carcinogenic or mutagenic potential or potential to adversely affect male or female fertility have not been performed. PREGNANCY Category C. Animal reproduction studies have not been conducted with GaviLyte- C with flavor pack, and it is not known whether GaviLyte- C with flavor pack can affect reproductive capacity or harm the fetus when administered to a pregnant patient.

GaviLyte- C with flavor pack should be given to a pregnant patient only if clearly needed. PEDIATRIC USE Safety and effectiveness in pediatric patients have not been established. GERIATRIC USE Published literature contains isolated reports of serious adverse reactions following the administration of PEG-ELS products in patients over 60 years of age.

These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and "butterfly-like" infiltrate on chest x-ray after vomiting and aspirating PEG.

📄 Package Label / Principal Display Panel 26 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Gavilyte-C with Flavor Pack (PEG-3350 (240g) and electrolytes for oral solution, USP) with flavor pack Label Lemon Flavor Pack Label lemon flavor

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
79.3K
Units reimbursed last 4 qtrs
313.3M
Gross reimbursed last 4 qtrs
$1.76M
Avg / prescription
$22.21
Avg / unit
$0.0056
Latest quarter Q1 2026
17.9KRx
Medicaid pays / mL
$0.0056
gross reimbursed
vs
NADAC / mL
$0.0039
acquisition cost
=
Spread
+$0.0017
+44% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
63% FFS 37% MCO
Fee-for-service · 49,733 Rx Managed care · 29,599 Rx
State Medicaid map
Alaska: no data reported AK Maine: 724,000 units · 51,900 per 100k residents ME Washington: 8,996,000 units · 115,156 per 100k residents WA Idaho: 1,188,000 units · 60,489 per 100k residents ID Montana: no data reported MT North Dakota: 116,000 units · 14,815 per 100k residents ND Minnesota: 4,776,400 units · 83,256 per 100k residents MN Wisconsin: 6,100,000 units · 103,215 per 100k residents WI Michigan: 3,260,000 units · 32,480 per 100k residents MI New York: 36,599,000 units · 187,006 per 100k residents NY Vermont: 48,000 units · 7,419 per 100k residents VT New Hampshire: no data reported NH Oregon: 4,936,000 units · 116,608 per 100k residents OR Nevada: 14,792,002 units · 463,118 per 100k residents NV Wyoming: no data reported WY South Dakota: 76,001 units · 8,270 per 100k residents SD Iowa: 336,000 units · 10,477 per 100k residents IA Illinois: 2,236,001 units · 17,818 per 100k residents IL Indiana: 6,996,001 units · 101,953 per 100k residents IN Ohio: 5,859,871 units · 49,723 per 100k residents OH Pennsylvania: 11,282,001 units · 87,046 per 100k residents PA New Jersey: 877 units · 9.4 per 100k residents NJ Massachusetts: 6,216,000 units · 88,787 per 100k residents MA California: 119,542,410 units · 306,794 per 100k residents CA Utah: 912,000 units · 26,690 per 100k residents UT Colorado: 11,252,000 units · 191,426 per 100k residents CO Nebraska: 700,000 units · 35,389 per 100k residents NE Missouri: 4,976,000 units · 80,310 per 100k residents MO Kentucky: 1,808,400 units · 39,956 per 100k residents KY West Virginia: no data reported WV Virginia: 7,092,004 units · 81,368 per 100k residents VA Maryland: 14,065,158 units · 227,592 per 100k residents MD Connecticut: 2,664,001 units · 73,652 per 100k residents CT Rhode Island: 404,354 units · 36,927 per 100k residents RI Arizona: 5,624,000 units · 75,683 per 100k residents AZ New Mexico: 876,000 units · 41,438 per 100k residents NM Kansas: no data reported KS Arkansas: 408,000 units · 13,303 per 100k residents AR Tennessee: 3,612,400 units · 50,693 per 100k residents TN North Carolina: 4,168,000 units · 38,468 per 100k residents NC South Carolina: 2,636,000 units · 49,060 per 100k residents SC Delaware: 215 units · 20.9 per 100k residents DE Oklahoma: 2,932,354 units · 72,350 per 100k residents OK Louisiana: 4,944,000 units · 108,089 per 100k residents LA Mississippi: 1,112,000 units · 37,823 per 100k residents MS Alabama: 256,000 units · 5,012 per 100k residents AL Georgia: 2,792,000 units · 25,315 per 100k residents GA D.C.: 616,181 units · 90,748 per 100k residents DC Hawaii: 3,824,000 units · 266,481 per 100k residents HI Texas: 1,273,000 units · 4,173 per 100k residents TX Florida: 320,000 units · 1,415 per 100k residents FL
Units reimbursed · per 100k residents
9.4463,118
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Nevada 463,118 /100k
2 California 306,794 /100k
3 Hawaii 266,481 /100k
4 Maryland 227,592 /100k
5 Colorado 191,426 /100k
6 New York 187,006 /100k
7 Oregon 116,608 /100k
8 Washington 115,156 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
← 43386-0050-19 · Lupin 43386-0069-60 · Lupin →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.